Auxilium Pharmaceuticals Beats Analyst Estimates on EPS
Auxilium Pharmaceuticals (NAS: AUXL) reported earnings on Feb. 26. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Auxilium Pharmaceuticals met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly. GAAP earnings per share increased.
Margins grew across the board.
Auxilium Pharmaceuticals recorded revenue of $172.5 million. The eight analysts polled by S&P Capital IQ wanted to see a top line of $172.5 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $73.3 million.
EPS came in at $1.83. The seven earnings estimates compiled by S&P Capital IQ averaged $1.71 per share. GAAP EPS were $1.83 for Q4 versus -$0.25 per share for the prior-year quarter.
For the quarter, gross margin was 83.7%, 620 basis points better than the prior-year quarter. Operating margin was 52.5%, much better than the prior-year quarter. Net margin was 52.5%, much better than the prior-year quarter.
Next quarter's average estimate for revenue is $81.1 million. On the bottom line, the average EPS estimate is $0.08.
Next year's average estimate for revenue is $344.4 million. The average EPS estimate is $0.11.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 132 members out of 187 rating the stock outperform, and 55 members rating it underperform. Among 57 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 32 give Auxilium Pharmaceuticals a green thumbs-up, and 25 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Auxilium Pharmaceuticals is outperform, with an average price target of $22.45.
- Add Auxilium Pharmaceuticals to My Watchlist.
The article Auxilium Pharmaceuticals Beats Analyst Estimates on EPS originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.